Premium
Immunosuppression Minimization Trials in Liver Transplantation: Can We Predict Humoral Response to Assess Eligibility?
Author(s) -
Meszaros Magdalena,
UrsicBedoya Jose,
Faure Stéphanie,
Pageaux GeorgesPhilippe
Publication year - 2019
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.30345
Subject(s) - immunosuppression , liver transplantation , medicine , human leukocyte antigen , immunology , transplantation , antibody , clinical trial , intensive care medicine , antigen
We have read with great interest the article by Jucaud et al. (1) reporting that de novo donor-specific HLA antibodies (dnDSA) development during immunosuppression (IS) withdrawal in liver transplantation (LT) was associated with acute rejection and prevented further attempts of IS withdrawal. This article is protected by copyright. All rights reserved.